Applications of 2-Cyclopropyl-4-(4-Fluorophenyl)-Quinolyl-3-Methanol in Industrial Manufacturing

As a specialized producer, we supply 2-Cyclopropyl-4-(4-Fluorophenyl)-Quinolyl-3-Methanol to regulated sectors that require advanced quinoline derivatives for high-value synthesis processes. Below, we outline principal downstream industrial applications, highlighting key technical, compliance, and production aspects for each scenario.

1. Active Pharmaceutical Ingredient (API) Intermediate for CNS Drugs

This compound serves as a core intermediate in the multi-step synthesis of selective central nervous system (CNS) modulators, particularly in the development of novel psychoactive agents. It enters at the heterocycle elaboration phase, where its unique structure imparts target selectivity and metabolic stability to the end API. Downstream users integrate precise gram-scale batches under stringent quality controls, adjusting process temperature and pH to maintain chirality and minimize impurity formation during coupling and reduction steps. End use culminates in finished API substances for oral and parenteral dosage forms after subsequent purification and salt formation.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP <823>, <701>, and <1086> relevant analytical procedures
• 21 CFR Part 210/211—cGMP regulations (US FDA)
• European Pharmacopoeia Monographs (for downstream APIs)

Typical usage ratio

• Applied at 5–15% molar ratio relative to target API core structure per batch, adjusted depending on scalability and conversion yield

Downstream process integration

• Incorporated in the secondary synthesis step after initial scaffold assembly, directly involved in coupling reactions and chiral resolution phases

Final product types

• Active pharmaceutical ingredients for CNS therapies
• Small molecule reference standards for bioanalytical studies
• Phase II/III clinical trial materials
• Pharmaceutical intermediates for process R&D

2. Advanced Intermediate for Oncology Compound Synthesis

This quinoline derivative enables the construction of fluorinated pharmaceutical scaffolds critical in next-generation oncology therapeutics. Leading pharmaceutical producers utilize it during the controlled fluorination and cyclization stages of kinase inhibitor manufacture, enabling high selectivity and purity in the resultant compound. Close control of reaction stoichiometry, temperature, and solvent profile are necessary in compliance with cGMP standards, notably for high-potency drug substances. Finished products include oral and injectable anticancer drugs after final downstream functionalization and formulation.

Industry compliance standards

• ICH Q11—Development and Manufacture of Drug Substances
• EMA Guideline on the Manufacture of the Finished Dosage Form
• USP-NF relevant monographs for oncology APIs
• GMP certification for high-containment manufacturing

Typical usage ratio

• Used in 3–7% molar excess depending on desired yield and purity for oncological intermediate production

Downstream process integration

• Charged during the late-stage coupling and fluorination via Mitsunobu or Suzuki processes; ensures the introduction of cyclopropyl-fluorophenyl motifs

Final product types

• Small-molecule kinase inhibitors
• Fluorinated heterocyclic API precursors
• Oral solid dosage cancer medications
• Investigational oncologic drug substances

3. Research-Grade Reference Compound for Medicinal Chemistry

Certified laboratories and research groups require this compound as a high-purity reference standard for SAR (structure-activity relationship) and ADME (absorption, distribution, metabolism, elimination) profiling. It is supplied with full analytical documentation and batch-specific impurity profiles, commonly used in stability investigations, metabolite identification, and to benchmark synthetic analogues. It enters discovery workflows at the hit-to-lead and lead optimization stages, assisting in screening candidate drug molecules for receptor binding and metabolic resistance.

Industry compliance standards

• ISO/IEC 17025 certified laboratory testing
• OECD Good Laboratory Practice (GLP) Principles
• USP <1225>—Analytical Method Validation
• REACH Annex XVII (for import/export, non-clinical use)

Typical usage ratio

• Employed at microgram to milligram scale per study, determined by the specific assay and required accuracy of analytical detection

Downstream process integration

• Direct injection into LC-MS/MS or NMR workflows; also dissolved for cell-based functional assays and stability challenge studies

Final product types

• Reference standards for analytical method development
• Control compounds for pharmacological screening
• Analytical standards for regulatory submission data
• SAR/ADME study reagents

4. Fine Chemical Intermediate for Specialty Compound Synthesis

Chemical manufacturers use this molecular building block during synthesis of complex specialty compounds, particularly where fluorinated and cyclopropylated motifs are needed for agrochemical actives or specialty polymer initiators. The compound’s controlled reactivity allows introduction of functional groups via catalytic hydrogenation or halogen exchange, often performed under anhydrous, inert gas conditions to ensure maximum yield. Product batches are subject to analytical monitoring for unreacted starting material and substructure verification before further downstream derivatization.

Industry compliance standards

• ISO 9001:2015—Quality Management in Fine Chemical Production
• REACH Pre-registration (EU)
• Responsible Care® Program (International Council of Chemical Associations)
• GHS-based hazard communication (CLP/EU, OSHA/US)

Typical usage ratio

• Charged between 8–20% by mass of batch, ratios are adjusted according to requirement of target compound and conversion efficiency

Downstream process integration

• Loaded during intermediate or final synthetic step for structural motif transfer; included as key input in pilot or full-scale production reactors

Final product types

• Agrochemical active intermediates
• Advanced specialty additives
• Functionalized monomers for specialty polymers
• Fine chemical reagents for R&D